This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors
- NCT番号
- NCT05907980
- 他の登録番号
- jRCT2031230072
- 治験責任医師
- 清水俊雄
- 製薬企業（治験依頼者）
- Chugai Pharma USA, Inc.
- 参加条件
Towards “Five-Stars” Phase 1 Center of Excellence
Department of New Experimental Therapeutics
Early-Phase 1 Drug Development Service